Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eradication of H. pylori infection in Belgium: bismuth versus first line therapy
2016-000228-24Phase 4Completed
- Sponsor
- UZ Brussel
- Start
- Jan 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amoxicillin, clarithromycin, bismuth subcitrate, metronidazole and tetracycline in Helicobacter-associated gastritis and Helicobacter pylori infection (2 arms), sponsored by UZ Brussel. Primary endpoint: H. pylori eradication. Started Jan 2016; status: completed.
02
Drugs
amoxicillinclarithromycinbismuth subcitratemetronidazoletetracycline
03
Conditions
Helicobacter-associated gastritisHelicobacter pylori infection
Beyond the preview
Go deeper on 2016-000228-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000228-24.